Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.
暂无分享,去创建一个
P. Hersey | X. D. Zhang | T. Nguyen | T. Nguyen | T. Nguyen | T. Nguyen | Xu Dong Zhang | P. Hersey
[1] D. Lawrence,et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.
[2] T. Griffith,et al. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. , 1998, Journal of immunology.
[3] P. Hersey,et al. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. , 1999, Cancer research.
[4] I. Herr,et al. Inhibition of Nuclear Factor κB Activation Attenuates Apoptosis Resistance in Lymphoid Cells , 1998 .
[5] P. Hersey,et al. TNF-Related Apoptosis-Inducing Ligand-Induced Apoptosis of Melanoma Is Associated with Changes in Mitochondrial Membrane Potential and Perinuclear Clustering of Mitochondria1 , 2000, The Journal of Immunology.
[6] Margot Thome,et al. Inhibition of death receptor signals by cellular FLIP , 1997, Nature.
[7] K. Okumura,et al. Type I Interferons (IFNs) Regulate Tumor Necrosis Factor–related Apoptosis-inducing Ligand (TRAIL) Expression on Human T Cells: A Novel Mechanism for the Antitumor Effects of Type I IFNs , 1999, The Journal of experimental medicine.
[8] T. Gura. How TRAIL Kills Cancer Cells, But Not Normal Cells , 1997, Science.
[9] P. Hersey,et al. Immunohistological Examination Of The Relationship Between Metastatic Potential And Expression Of Adhesion Molecules And ‘Selectins’ On Melanoma Cells , 1994, Pathology.
[10] John C. Lee,et al. Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.
[11] S. Sharrow,et al. Analysis of Flow Cytometry Data , 1991, Current protocols in immunology.
[12] C. Heusser,et al. Detection of intracellular cytokines by flow cytometry. , 1993, Journal of immunological methods.
[13] P. Hersey,et al. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] S. Marsters,et al. Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.
[15] T. Griffith,et al. TRAIL: a molecule with multiple receptors and control mechanisms. , 1998, Current opinion in immunology.
[16] M. Weller,et al. APO2 ligand: a novel lethal weapon against malignant glioma? , 1998, FEBS letters.
[17] Tom Maniatis,et al. The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB , 1994, Cell.
[18] P. Hersey,et al. Differential Localization and Regulation of Death and Decoy Receptors for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Human Melanoma Cells1 , 2000, The Journal of Immunology.
[19] C. Smith,et al. Functional analysis of TRAIL receptors using monoclonal antibodies. , 1999, Journal of immunology.
[20] A. Fornace,et al. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. , 1998, Cancer research.
[21] A. Goldberg,et al. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. , 1994, Cell.
[22] C. Rauch,et al. Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.
[23] I Nicoletti,et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.
[24] P. Hersey,et al. The Role of NF-κB in TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis of Melanoma Cells1 , 2001, The Journal of Immunology.
[25] 松原 弘樹,et al. 腎癌に対するTNF-related Apoptosis-inducing Ligand(TRAIL)を用いたアポトーシス誘導による分子標的治療の検討 , 2003 .
[26] U. Zabel,et al. Nuclear uptake control of NF‐kappa B by MAD‐3, an I kappa B protein present in the nucleus. , 1993, The EMBO journal.
[27] S. Ruben,et al. TRAIL ( Apo-2 L ) and TRAIL Receptors in Human Placentas : Implications for Immune Privilege 1 , 1999 .
[28] C A Smith,et al. Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.